Akebia Ther Company Insiders
AKBA Stock | USD 2.30 0.01 0.44% |
Akebia Ther employs about 167 people. The company is managed by 20 executives with a total tenure of roughly 30 years, averaging almost 1.0 years of service per executive, having 8.35 employees per reported executive. Analysis of Akebia Ther's management performance can provide insight into the company performance.
Steven Burke President Senior Vice President Chief Medical Officer |
Michel Dahan President Senior Vice President and Chief Business Officer |
Akebia |
Akebia Ther Management Team Effectiveness
The company has return on total asset (ROA) of (0.0937) % which means that it has lost $0.0937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5345) %, meaning that it created substantial loss on money invested by shareholders. Akebia Ther's management efficiency ratios could be used to measure how well Akebia Ther manages its routine affairs as well as how well it operates its assets and liabilities.Akebia Ther Workforce Comparison
Akebia Ther is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 892. Akebia Ther retains roughly 167 in number of employees claiming about 19% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.33) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.33. Akebia Ther Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akebia Ther insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akebia Ther's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Akebia Ther insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Frieson Ron over a week ago Disposition of 20100 shares by Frieson Ron of Akebia Ther at 0.45 subject to Rule 16b-3 | ||
Rogers Michael W over two months ago Acquisition by Rogers Michael W of 30000 shares of Akebia Ther subject to Rule 16b-3 | ||
Steven Burke over six months ago Disposition of 6613 shares by Steven Burke of Akebia Ther at 0.8775 subject to Rule 16b-3 | ||
Ostrowski Erik over six months ago Acquisition by Ostrowski Erik of 350000 shares of Akebia Ther subject to Rule 16b-3 | ||
Gilman Steven C over six months ago Acquisition by Gilman Steven C of 30000 shares of Akebia Ther subject to Rule 16b-3 | ||
Gilman Steven C over six months ago Acquisition by Gilman Steven C of 30000 shares of Akebia Ther subject to Rule 16b-3 | ||
Adams Adrian over six months ago Acquisition by Adams Adrian of 45000 shares of Akebia Ther at 1.07 subject to Rule 16b-3 | ||
Michel Dahan over six months ago Disposition of 34840 shares by Michel Dahan of Akebia Ther at 1.26 subject to Rule 16b-3 |
Akebia Ther Notable Stakeholders
An Akebia Ther stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Akebia Ther often face trade-offs trying to please all of them. Akebia Ther's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Akebia Ther's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John MBA | President, CEO | Profile | |
Steven Burke | Senior Vice President Chief Medical Officer | Profile | |
Michel Dahan | Senior Vice President and Chief Business Officer | Profile | |
CGMA CPA | CFO VP | Profile | |
Nicole Hadas | Sr. VP, General Counsel and Secretary | Profile | |
Kristie Bolieau | VP Controller | Profile | |
Nicole JD | Chief VP | Profile | |
Mercedes Carrasco | Director Communications | Profile | |
David Spellman | CFO VP | Profile | |
Tracey Vetterick | Vice Administration | Profile | |
Thierry Bilbault | VP Devel | Profile | |
Erik MBA | Senior Officer | Profile | |
Douglas MBA | Vice Strategy | Profile | |
Nicholas Grund | Senior Officer | Profile | |
Carolyn Rucci | Senior Counsel | Profile | |
Kimberly Garko | Senior Officer | Profile | |
Meredith Bowman | Senior Officer | Profile | |
Steven MD | Senior Officer | Profile | |
Richard Malabre | Chief Officer | Profile | |
Violetta Cotreau | Chief VP | Profile |
About Akebia Ther Management Performance
The success or failure of an entity such as Akebia Ther often depends on how effective the management is. Akebia Ther management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Akebia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Akebia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 426 people.
Please note, the presentation of Akebia Ther's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akebia Ther's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Akebia Ther's management manipulating its earnings.
Akebia Ther Workforce Analysis
Traditionally, organizations such as Akebia Ther use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Akebia Ther within its industry.Akebia Ther Manpower Efficiency
Return on Akebia Ther Manpower
Revenue Per Employee | 1.2M | |
Revenue Per Executive | 9.7M | |
Net Loss Per Employee | 310.9K | |
Net Loss Per Executive | 2.6M | |
Working Capital Per Employee | 109.5K | |
Working Capital Per Executive | 914K |
Complementary Tools for Akebia Stock analysis
When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Transaction History View history of all your transactions and understand their impact on performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |